Navigation Links
Breast cancer heterogeneity no barrier to predictive testing, study shows
Date:5/2/2013

Lugano-CH, Brussels-BE, 2 May 2013 -- Breast cancers contain many different cell types with different patterns of gene expression, but a new study provides reassurance that this variability should not be a barrier to using gene expression tests to help tailor cancer treatments to individual patients.

The findings were reported at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. The IMPAKT meeting presents cutting edge, 'translational' breast cancer research that is beginning to have an impact for patients.

In recent years it has become clear that breast cancers contain a variety of different cell types. An important result of this heterogeneity is that different biopsy specimens from a single breast cancer tumour can exhibit significant variability in genes expression.

This is a major concern for doctors seeking to understand which patients are likely to benefit from drugs designed to be effective against tumour cells with particular genetic characteristics. A number of studies at this year's IMPAKT conference consider this issue.

In one study, Dr Michał Jarząb and colleagues from the Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Poland took a total of 78 different biopsies from 26 individual tumours to assess the degree of genomic variation, and its impact on a set of 32 different prognostic and predictive multi-gene signatures.

"Some genomic tests have proven very useful in breast cancer, but in other important areas we have not achieved optimal results," Dr Jarząb explains. "One of these areas where we haven't done so well is in deciding whether a particular patient would benefit from certain type of chemotherapy or not, based on the material from pre-surgical needle biopsies. We hypothesized that some genomic tests may be prone to the heterogeneity of starting material and provide not reliable results."

The researchers performed gene expressio
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Big data analysis identifies prognostic RNA markers in a common form of breast cancer
2. Cold winters freezing out breast cancer treatment
3. Identified as responsible for breast and ovarian hereditary cancer 3 mutations at BRCA1 gene
4. An important discovery in breast cancer by IRCM researchers
5. UCLA researchers find nanodiamonds could improve effectiveness of breast cancer treatment
6. IMPAKT -- Translational research breast cancer conference
7. LSUHSC research discovers new drug target for metastatic breast cancer
8. AACR news: Studies show increasing evidence that androgen drives breast cancer
9. AACR news: Six2 homeoprotein allows breast cancer cells to detach and metastasize
10. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
11. Certain breast cancers have a trait that could be attacked by new therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2014)... Stem cells the body,s master cells demonstrate ... level, according to a study published today from scientists ... as auxeticity is one which may have application ... Most materials when stretched will contract. For example, if ... will get thinner. The opposite is also true: squeeze ...
(Date:4/20/2014)... pancreatic cancers also promote drug-resistance and ultimately spur tumor ... School of Medicine have discovered a molecule, or biomarker, ... appears responsible for inducing tumor metastasis by enhancing the ... findings, published in the April 20, 2014 online issue ... new therapeutic opportunities for reversing drug resistance in a ...
(Date:4/20/2014)... Although doctors have long known that people with Down ... leukemia (ALL) during childhood, they haven,t been able to ... Institute investigators has uncovered a connection between the two ... the journal Nature Genetics , the researchers track ... abnormality in Down syndrome to the cellular havoc that ...
Breaking Biology News(10 mins):Bulletproof nuclei? Stem cells exhibit unusual absorption property 2Cancer stem cells linked to drug resistance 2Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3
... key step toward providing patients with treatments based on their ... Genomics Consortium (IGC) have launched a new joint venture that ... Called Paradigm, the new nonprofit company brings together the expertise ... using genetic information to understand and treat disease. Beginning ...
... Aug. 16, 2012 Reportlinker.com announces that ... in its catalogue: Booming ... http://www.reportlinker.com/p0946283/Booming-CCTV-Market-in-Asia-Forecast-to-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... market has been experiencing significant growth due ...
... Aug. 15, 2012 DNA sequencing is rapidly getting faster ... patients will be able to use this information. In ... from around the world are vying to interpret the ... cause remains a mystery—with the goal of establishing "best ...
Cached Biology News:Creating a future of personalized medicine: U-M forms joint venture for DNA diagnostics 2Booming CCTV Market in Asia Forecast to 2014 2Booming CCTV Market in Asia Forecast to 2014 3Thirty teams compete to interpret three families' genomes 2Thirty teams compete to interpret three families' genomes 3Thirty teams compete to interpret three families' genomes 4Thirty teams compete to interpret three families' genomes 5
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)...  3D Communications, a leading provider of strategic communications services to corporations ... in the United States and ... , JD, is returning to the firm,s Washington, D.C. ... after more than two years of service as Associate Commissioner for ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility ... of Product Strategy. In this role, Michelle will work with ... guide in the development of iLab products. Her main goal ... benefit to the scientific community by offering the most advanced, ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... (OTC Bulletin Board: WDST ) ( www.Regenicin.com ... Christopher A. Hadsall, whose primary responsibilities will be to ... as Chief Operating Officer.  Mr. Hadsall brings 12 years ... instrumental in working with various military groups to build ...
... Texas, Oct. 5 C3i, the leader in technology ... (BMS), a leading global biopharmaceutical company, will deliver a ... the newest version of Oracle Clinical/Remote Data Capture (OCRDC) ... the Oracle Health Sciences User Group conference (OHSUG) in ...
... Technologies, Inc. (ISTO), an  orthobiologics company with a cell-based ... patient enrollment in the Phase I clinical study for ... designed for the treatment of discogenic back pain. The ... All patients enrolled in the trial suffered from persistent ...
Cached Biology Technology:Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer 2Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer 3C3i and Bristol-Myers Squibb to Discuss the Effects of Oracle Clinical 4.5.3 Zero Footprint on Support Services at the Oracle Health Sciences User Group Conference 2ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 2ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 3
Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
... Extracts are optimized for maximum packaging efficiencies ... high efficiency extracts (> 109 pfu/g with ... a library containing at least 5 ... extracts are made from a specially designed ...
... Panorama Mouse/Rat Tissue Extract Protein Array Kit ... various tissue extracts. The expression of a ... a protein specific antibody. When the antibody ... by a sensitive chemiluminescent or fluorescent signal ...
... offers pre-validated SNP sequencing ... amplicons within 93 genes ... and more than 80 ... assays were developed and ...
Biology Products: